Points represent individual individuals; ns represents non-significant

Points represent individual individuals; ns represents non-significant. Image_1.pdf (258K) GUID:?8C3EE8D8-F457-40A6-9F64-1444FC0E54F9 Supplementary Number?2: Immunization with RBD9.1 antigenic peptide efficiently induced neutralizing antibody production in Balb/c mice. (reddish) to alanine. (F) Sequence positioning for the RBD proteins of SARS-CoV-2 and SARS-CoV. The RBM region was designated in red, and the same amino acid sequence of the RBD protein of SARS-CoV-2 and SARS-CoV was designated in light blue. The amino acid sequence of RBD9.1 in SARS-CoV-2 RBD is marked with green dots. (G) Sequence alignment within the amino acid sequence of RBD9.1 of WT, P.1, B.1.1.7, B.1.351, B.1.617.1 and B.1.617.2 strains. Image_2.pdf (1.9M) GUID:?6789AD55-91A1-4AF2-8D1A-24FC7231512D Supplementary Number?3: Related to Number?3 . (A) Circulation cytometric diagram of the proportion of CD19-CD138+ plasma cells. (B) ELISPOT results of RBD-specific plasma cells in the spleen and bone marrow of mice after last immunization. Results were indicated as the numbers of RBD-specific IgG places per 5 105 splenocytes of each mouse, subtracted those from A-3 Hydrochloride your related DMSO organizations. The activation with an equal volume of press was performed as the bad control. Data were representative of two self-employed experiments. Image_3.pdf (1.6M) GUID:?64DB3B55-A1FD-45AF-A065-7C86316FF891 Supplementary Figure?4: Related to Number?4 . The manifestation of CD25 (A) and CD69 (B) (gated on CD4+ T cells) within the 7th day time after the last immunization. Image_4.pdf (1.4M) GUID:?79E76BE5-FF95-47B7-A2CF-31CA5E6E7959 Supplementary Figure?5: Related to Number?4 . The manifestation of CD137 (A) and CD69 (B) (gated on CD8+ T cells) after 10 g/mL P45 or HBV peptide activation for A-3 Hydrochloride 24 hours, normal press was used as bad control. Image_5.pdf (2.0M) GUID:?3EAEB1D7-9FB5-4581-B3E4-5B1ECA10ECEB Supplementary Number?6: Related to Number?4 . The manifestation of IFN- gated on CD8+ T cells (A) and on CD4+ T cells (B) within the 10th day time after the last immunization. Image_6.pdf (298K) GUID:?DC8197C0-BFF5-422D-8B9D-C2F64B3E8E2B Supplementary Number?7: Related to Number?5 . (A) Activation with R848 and IL-2 for 6 days, the ELISPOT picture showed the number of RBD-specific IgG places per 5 105 splenocytes of each mouse. (B) The binding capabilities of 10-collapse serially diluted mouse serum to SARS-CoV-2 RBD recombinant protein. The percentage of Tn (CD62L+ CD44-), Te (CD62L- CD44-), Tem (CD62L- CD44+) and Tcm (CD62L+ CD44+) of CD8+ (C) or CD4+ T (D) cells on day time 10 and day time 94 after the last immunization. Image_7.pdf (1.8M) GUID:?71E80376-4B48-45A9-9C3A-A9D9A4F795F0 Supplementary Figure?8: Related to Number?6 . The manifestation of CD69 (A) and CD137 (B) (gated on CD8+ T cells of immune mice) were recognized by circulation cytometry after 10 g/mL RBD, RBD9.1 or HBV peptide activation for 24 hours, normal press was the bad control. Image_8.pdf (2.7M) GUID:?5958ED46-C508-45FC-A658-7C3BAAB13ABF Supplementary Table?1: The information of Organizations and OD 405nm were listed in Supplementary Table?1 . And the threshold for grouping is definitely 1.788, in TLR1 accordance with the average OD value of 31 samples. Table_1.pdf (50K) GUID:?B1F59BE7-7111-401A-B30E-20F463FC2B00 Supplementary Table?2: The clinical info and RBD-hACE2 connection inhibition titers (IC50) and SARS-CoV-2 pseudovirus neutralization A-3 Hydrochloride titers (IC50) were listed in Table?2 . Table_2.pdf (1.8M) GUID:?5566ACC4-20C1-4388-B958-3F5CBD304423 Supplementary Table?3: The information of immunized mice was listed in Table?3 . Table_3.pdf (1.1M) GUID:?C705020A-E3F2-4B99-B5DD-74186FBF6AAA Supplementary Table?4: The sequence info of SARS-COV-2 strains during RBD9.1 area were listed in Table?4 . Table_4.pdf (1.1M) GUID:?7D5B1EAB-95B5-4495-8F68-BFDAD4E2F9E0 Data Availability StatementThe initial contributions presented in the study are included in the article/ Supplementary Material . Further inquiries can be directed to the related author. Abstract Facing the imminent need for vaccine candidates with cross-protection A-3 Hydrochloride against globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants, we present a conserved antigenic peptide RBD9.1 with both T-cell and B-cell epitopes. RBD9.1 can be identified by coronavirus disease A-3 Hydrochloride 2019 (COVID-19) convalescent serum, particularly for those with high neutralizing potency. Immunization with RBD9.1 can successfully induce the production of the receptor-binding website (RBD)-specific antibodies in Balb/c mice. Importantly, the immunized sera show sustained neutralizing effectiveness against multiple dominating SARS-CoV-2 variant.